Trial NCT05132855
Publication Chuang C-H, medRxiv, 2022
Primary outcome on the report: Immunogenicity assessed 28 days after booster vaccination, including serum SARS-CoV-2 anti-spike IgG concentration, the 50% neutralizing antibody titers (NT50) against wild-type, alpha, delta and omicron variants, and IFN-γ secreting T cells specific to whole spike protein of the wild type.

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.